by New research published in the journal “Nature Communications” sheds light on a potential new function of Canagliflozin, a widely used sodium-glucose co-transporter 2 (SGLT2) inhibitor for diabetes treatment. The study, led by researchers from the University of California, San Francisco (UCSF), suggests that Canagliflozin may also play a significant role in the removal of senescent cells, which are linked to aging and various age-related diseases.
Senescent cells, also known as “zombie cells,” are no longer able to divide and perform their normal functions. They accumulate in the body as we age, contributing to various health issues, including diabetes, cardiovascular diseases, and neurodegenerative disorders. The UCSF team discovered that Canagliflozin can help eliminate these cells, providing a potential new avenue for treating not only diabetes but also age-related diseases.
The researchers conducted experiments on mice, administering Canagliflozin to obese mice with diabetes. They observed a significant reduction in senescent cells in various organs, including the pancreas, liver, and Artificial kidneys. The findings were further supported by in vitro studies, which demonstrated that Canagliflozin can induce senescent cell death in human cells.
The exact mechanism by which Canagliflozin eliminates senescent cells is still under investigation. However, the researchers believe that it may be related to the drug’s ability to increase the expression of a protein called NRF4, which plays a crucial role in the elimination of senescent cells.
These findings could have significant implications for the treatment of diabetes and age-related diseases. By targeting senescent cells, Canagliflozin could potentially offer a more comprehensive approach to managing diabetes and reducing the risk of age-related health issues. Further research is needed to fully understand the potential of this novel application of Canagliflozin.
In conclusion, a recent study published in “Nature Communications” reveals that Canagliflozin, a widely used diabetes medication, may also play a role in eliminating senescent cells. This discovery could lead to new and more effective treatments for diabetes and age-related diseases.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
